For the Quarter Ending September 2025
North America
• In the US, Tenofovir Disoproxil Fumarate Price Index rose Q3 2025, driven by increasing production costs.
• Production costs increased from 2.6% PPI rise in August 2025 and 3.0% CPI in September 2025.
• Robust demand for HIV and Hepatitis B treatments supported Tenofovir Disoproxil Fumarate in Q3 2025.
• Tenofovir Disoproxil Fumarate Price Forecast suggests upward pressure from rising input costs and strong demand.
• Fumaric acid feedstock costs declined in Q3 2025 due to lower freight costs and ample inventories.
• US retail sales increased 5.42% in September 2025, supporting healthcare funding and TDF demand.
• Low 4.3% unemployment rate in September 2025 enhanced healthcare access, positively impacting TDF demand.
• Industrial production rose 0.1% in September 2025, while consumer confidence declined to 94.2.
Why did the price of Tenofovir Disoproxil Fumarate change in September 2025 in North America?
• Producer prices increased 2.6% in August 2025, elevating Tenofovir Disoproxil Fumarate production expenses.
• Robust demand for HIV and Hepatitis B treatments supported Tenofovir Disoproxil Fumarate pricing in Q3 2025.
• US tariffs on pharmaceutical imports in July-September 2025 directly raised manufacturing costs.
Europe
• In Germany, the Tenofovir Disoproxil Fumarate Price Index fell quarter-over-quarter in Q3 2025, influenced by softening feedstock costs.
• Production costs for Tenofovir Disoproxil Fumarate trended lower, with propylene, fumaric acid, and naphtha prices weakening in Q3 2025.
• The Manufacturing Index contracted in Q3 2025, signaling a slowdown in industrial activity impacting supply chains.
• Industrial production declined 1.0% year-over-year in September 2025, affecting raw material availability and costs.
• The Producer Price Index decreased 1.7% year-over-year in September 2025, reducing pharmaceutical manufacturing expenses.
• Ample fumaric acid inventories in Q3 2025 contributed to downward pressure on intermediate chemical prices.
• The Consumer Price Index rose 2.4% year-over-year in September 2025, indicating broader inflationary pressures on operational costs.
• The Tenofovir Disoproxil Fumarate price outlook indicates stability or slight declines, driven by cost reductions and ample inventories.
Why did the price of Tenofovir Disoproxil Fumarate change in September 2025 in Europe?
• Softening propylene, fumaric acid, and naphtha feedstock costs significantly reduced production expenses in Q3 2025.
• The Producer Price Index fell 1.7% year-over-year in September 2025, directly lowering manufacturing costs.
• Ample fumaric acid inventories in Q3 2025 contributed to increased supply and downward pressure on intermediate prices.
APAC
• In China, Tenofovir Disoproxil Fumarate prices fell in Q3 2025, due to declining production costs and soft demand.
• Production costs declined, with the Producer Price Index (PPI) falling 2.3% year-on-year in September 2025.
• Fumaric acid feedstock costs decreased in China during Q3 2025, driven by sluggish demand and oversupply.
• Propylene feedstock supply significantly exceeded local demand in 2025, further easing Tenofovir Disoproxil Fumarate production expenses.
• Domestic consumer demand remained soft in Q3 2025, as the Consumer Price Index (CPI) declined 0.3% year-on-year.
• Consumer confidence was pessimistic at 89.6 in September 2025, indirectly impacting healthcare spending and patient access.
• Industrial production grew 6.5% year-on-year in September 2025, despite a contracting Manufacturing Index.
• Elevated overall chemical inventories in China during 2025, including high fumaric acid stocks, contributed to oversupply.
• China's chemical overcapacity impacted global supply chains, increasing competition and downward price pressure.
Why did the price of Tenofovir Disoproxil Fumarate change in September 2025 in APAC?
• The Producer Price Index (PPI) fell 2.3% year-on-year in September 2025, reducing Tenofovir Disoproxil Fumarate production costs.
• The Consumer Price Index (CPI) declined 0.3% year-on-year in September 2025, reflecting soft domestic demand.
• High fumaric acid inventories and overall chemical overcapacity in Q3 2025 contributed to downward price pressure.
